833 studies found for:    Interferon alfa-2 OR Roferon-A (2a), Intron A (2b)[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Active, not recruiting Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma
Conditions: Lymphoma;   Precancerous/Nonmalignant Condition
Interventions: Biological: PEG-interferon alfa-2b;   Biological: Interferon alfa-2b;   Drug: Valproic Acid;   Drug: Zidovudine;   Genetic: Molecular Evaluation/Analysis of Malignant Clones of ATLL;   Genetic: NF-kB Inhibition
2 Completed Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Recurrent Renal Cell Cancer;   Stage III Melanoma;   Stage IV Melanoma;   Stage IV Renal Cell Cancer
Interventions: Biological: recombinant interferon alfa-2b;   Drug: amifostine/azacitidine
3 Active, not recruiting Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
Conditions: Stage IA Skin Melanoma;   Stage IB Skin Melanoma;   Stage IIA Skin Melanoma;   Stage IIB Skin Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
4 Terminated Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
Conditions: Breast Cancer;   Metastatic Cancer
Interventions: Biological: PEG-interferon alfa-2a;   Drug: Capecitabine
5 Terminated
Has Results
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Decitabine;   Drug: Interferon Alfa-2b
6 Completed
Has Results
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Peginterferon alfa-2a and ribavirin;   Drug: Peginterferon alfa-2a
7 Completed Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Regional Gastrointestinal Carcinoid Tumor
Interventions: Biological: PEG-interferon alfa-2b;   Biological: bevacizumab;   Other: laboratory biomarker analysis
8 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
9 Completed
Has Results
Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin
Conditions: Chronic Hepatitis C;   Hemodialysis
Intervention: Drug: Pegylated interferon alfa-2a and ribavirin
10 Terminated Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: peginterferon alfa-2b;   Drug: decitabine;   Other: laboratory biomarker analysis
11 Recruiting Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
Conditions: Conjunctival Intraepithelial Neoplasia;   Corneal Intraepithelial Neoplasia
Interventions: Drug: Mitomycin C;   Drug: Interferon Alfa-2b
12 Active, not recruiting Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4
Condition: Chronic Hepatitis C
Interventions: Drug: IFN alfa-2b XL 27 MUI + Ribavirin;   Drug: IFN alfa-2b XL 36 MUI + Ribavirin;   Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
13 Completed Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C
Condition: Hepatitis C
Intervention: Drug: Pegylated interferon alfa-2a
14 Unknown  Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.
Condition: Chronic Hepatitis C
Intervention: Biological: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin
15 Recruiting Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Aspirin
16 Terminated PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: PEG-interferon alfa-2b;   Drug: PEG-interferon alfa-2b
17 Completed Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Solid Tumors
Interventions: Drug: Sodium Stibogluconate;   Drug: Interferon Alpha-2b
18 Completed Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Condition: Stage IV Melanoma
Interventions: Biological: recombinant interferon alfa-2b;   Drug: cisplatin;   Drug: sodium stibogluconate;   Drug: dacarbazine;   Drug: vinblastine
19 Active, not recruiting Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine;   Biological: recombinant interferon alfa-2b;   Biological: recombinant vaccinia-CEA(6D)-TRICOM vaccine;   Biological: sargramostim
20 Unknown  Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
Condition: Non-melanomatous Skin Cancer
Interventions: Biological: PEG-interferon alfa-2a;   Drug: gefitinib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years